Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Dr. Burke on Research With Tafasitamab in Lymphoma

May 9th 2020

John M. Burke, MD, discusses research with tafasitamab (MOR208) in lymphoma.

Novel and Emerging Therapeutic Interventions in Relapsed and Refractory Diffuse Large B-Cell Lymphoma

May 8th 2020

A panel of experts discuss the current and emerging treatment landscape of relapsed/refractory diffuse large B-cell lymphoma.

Dr. Pagel on the Shift Toward Precision Medicine in Large Cell Lymphoma

May 7th 2020

John M. Pagel, MD, PhD, chief of the Hematologic Malignancies Program, and director, Hematopoietic Cell Transplantation Program, at Swedish Cancer Institute, discusses the shift toward precision medicine in large cell lymphoma.

More Data Needed to Tease Out Optimal Approaches in Non-Hodgkin Lymphoma

May 7th 2020

Sonali M. Smith, MD, sheds light on some of the recent advances in follicular lymphoma and mantle cell lymphoma, as well as the challenges that remain overall in non-Hodgkin lymphoma.

FDA Grants HQP1351 Orphan Drug Status in CML

May 4th 2020

The FDA has granted an orphan drug designation to HQP1351 for the treatment of patients with chronic myeloid leukemia.

Dr. Stone on Combinations With Venetoclax in AML

May 2nd 2020

Richard M. Stone, MD, director of the Adult Leukemia Program, Dana-Farber Cancer Institute, and professor of medicine, Harvard Medical School, discusses combinations with venetoclax (Venclexta) in acute myeloid leukemia (AML).

FDA Grants CC-486 Priority Review for Maintenance AML

May 1st 2020

The FDA has granted a priority review designation to CC-486 for the maintenance treatment of adult patients with acute myeloid leukemia.

Photodynamic Therapy SGX301 Continues to Impress in Phase 3 CTCL Trial Update

April 30th 2020

Updated data from the pivotal phase 3 FLASH trial showed that SGX301 (synthetic hypericin) continued to demonstrate strong clinical activity in patients with cutaneous T-cell lymphoma.

Positive Safety Profile Reported for Atezolizumab/Axi-Cel Combo in DLBCL

April 29th 2020

A manageable safety profile was observed for the combination of atezolizumab and the anti-CD19 chimeric antigen receptor T-cell therapy, axicabtagene ciloleucel, in patients with refractory diffuse large B-cell lymphoma.

FDA Approves Updated Dosing Schedule for Pembrolizumab

April 29th 2020

The FDA has approved an updated dosing schedule for pembrolizumab to include an every-6-weeks option at 400 mg across all indications in adult patients.

Universal Allogeneic CAR T-Cell Product Demonstrates Efficacy in a Cohort of Adult T-ALL

April 29th 2020

The first-in-clinic universal CAR T-cell therapy TruUCAR GC027 induced promising early response rates and demonstrated a manageable safety profile with no evidence of neurotoxicity events or graft-versus-host disease in adult patients with relapsed/refractory T-cell acute lymphoblastic leukemia.

Dr. Daver on Stem Cell Transplant Considerations in Hematologic Malignancies in Light of COVID-19

April 29th 2020

Naval G. Daver, MD, discusses the impact of COVID-19 on stem cell transplant for patients with hematologic malignancies and other measures put into place to prevent patients from infection.

Bispecific CD19/CD22 CAR T Cells Active in Pediatric Relapsed ALL

April 28th 2020

Treatment with CD19/22 chimeric antigen receptor CAR T cells induced a promising response in patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

Vecabrutinib Shows Evidence of Stable Disease in High-Risk B-Cell Malignancies

April 28th 2020

John N. Allan, MD, discusses the study results of a phase 1b/2 dose-escalation trial with vecabrutinib in patients with B-cell malignancies.

Dr. Thirman on the Rationale for Using SNDX-5613 in Acute Leukemias

April 28th 2020

Michael J. Thirman, MD, discusses the clinical rationale for using the investigational agent SNDX-5613 to treat a subtype of acute myeloid leukemia and acute lymphoblastic leukemia.

Dr. Rizvi on the Limitations of ABVD in Hodgkin Lymphoma

April 24th 2020

Syed Rizvi, MD, discusses the limitations of doxorubicin, bleomycin, vinblastine, and dacarbazine in Hodgkin lymphoma.

Dr. Grossbard on the Activity of Venetoclax in Follicular Lymphoma

April 24th 2020

Michael L. Grossbard, MD, discusses the activity of venetoclax in follicular lymphoma.

Dr. Altomare on the Challenges of Treating ITP

April 24th 2020

Ivy P. Altomare, MD, discusses some of the challenges of treating patients with immune thrombocytopenia.

Brentuximab Vedotin Plus Nivolumab Impresses in Older Patients With Hodgkin Lymphoma

April 24th 2020

Christopher A. Yasenchak, MD, discusses findings from the phase 2 trial with brentuximab vedotin and nivolumab in patients with newly diagnosed classical Hodgkin lymphoma.

Screening Is Critical Component of TA-TMA Management

April 23rd 2020

Christopher E. Dandoy, MD, MSc, discusses the clinical features of TA-TMA and the importance of close monitoring and intervention for patients at risk of developing the disorder.